DOI: /ijasbt.v1i ISSN This paper can be downloaded online at

Similar documents
Plasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension

Indian Journal of Basic & Applied Medical Research; December 2011: Issue-1, Vol.-1, P

THE EFFECT OF VITAMIN-C THERAPY ON HYPERGLYCEMIA, HYPERLIPIDEMIA AND NON HIGH DENSITY LIPOPROTEIN LEVEL IN TYPE 2 DIABETES

Lipoprotein (a): Is it important for Friedewald formula?

Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL

Association between Plasma Homocysteine Concentrations and Carotid Intima-Media Thickness in Patients with Coronary Artery Disease

Clinical Study of Lipid Profile Pattern in Acute Coronary Syndromes

The New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk

Friedewald formula. ATP Adult Treatment Panel III L D L Friedewald formula L D L = T- C H O - H D L - T G / 5. Friedewald formula. Friedewald formula

Tracking a Killer Molecule

Prediction of Cardiovascular Disease in suburban population of 3 municipalities in Nepal

Impact of Chronicity on Lipid Profile of Type 2 Diabetics

ASSOCIATION BETWEEN BODY MASS INDEX, LIPID PEROXIDATION AND CORONARY LIPID RISK FACTORS IN HYPOTHYROID SUBJECTS

ISCHEMIC HEART DISEASE: Role of Total Cholesterol: HDL C Ratio as an Important Indicator Compared to LDL C.

EXECUTIVE SUMMARY OF THE MINOR RESEARCH PROJECT Submitted to UNIVERSITY GRANTS COMMISSION

JMSCR Vol 05 Issue 05 Page May 2017

A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups

Chemistry Reference Ranges and Critical Values

Chemistry Reference Ranges and Critical Values

Association of Cardiovascular Risk Factors in Hypertensive Subjects with Metabolic Syndrome De ned by Three Different De nitions

REAGENTS. RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING

行政院國家科學委員會補助專題研究計畫成果報告

Review of guidelines for management of dyslipidemia in diabetic patients

The apolipoprotein story

Lipoprotein (a) Disclosures 2/20/2013. Lipoprotein (a): Should We Measure? Should We Treat? Health Diagnostic Laboratory, Inc. No other disclosures

Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies

Lipoprotein Particle Profile

Pattern of plasma lipoprotein (a) in Sudanese patients with coronary

COMPARISON OF APOLIPOPROTEIN CONCENTRATIONS AND VALUES OF APOB:APOAI

Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both

Reeju Manandhar, Chaofeng Sun. Original article

Mipomersen (ISIS ) Page 2 of 1979 Clinical Study Report ISIS CS3

THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS

Review of literature. Total Cholesterol (TC)

Pattern of dyslipidemia and evaluation of non-hdl cholesterol as a marker of risk factor for cardiovascular disease in type 2 diabetes mellitus

Study of rhythm disturbances in acute myocardial infarction in Government Dharmapuri Medical College Hospital, Dharmapuri

EFFICIENCY AND COST-EFFECTIVENESS OF DYSLIPIDEMIA SCREENING METHODS AMONG WORKERS IN BANGKOK

Martin/Hopkins Estimation, Friedewald and Beta- Quantification of LDL-C in Patients in FOURIER

The investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India

HIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES

The Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk

Approach to Dyslipidemia among diabetic patients

Lipoprotein(a) and lipid profiles of patients awaiting coronary artery bypass graft; a cross sectional study

Comparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients

Biomarkers (Novel) in Risk Assessment and Management of Cardiovascular Disease

Clinical study of Huxinkang tablet in treating unstable angina pectoris

Tina-quant Lipoprotein (a) Gen. 2 For accurate and reliable assessment of cardiovascular risk

Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease

Katsuyuki Nakajima, PhD. Member of JCCLS International Committee

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

Cardiovascular Disease

Lipid Risk Factors (Novel) in Risk Assessment and Management of Cardiovascular Disease

Non-fasting Lipid Profile Getting to the Heart of the Matter! Medimail Dec 2017

Ischemic Heart Disease

sad EFFECTIVE DATE: POLICY LAST UPDATED:

Keywords: Type 2 DM, lipid profile, metformin, glimepiride ABSTRACT

High-Density Lipoprotein Subclass Testing in the Diagnosis and Management of Cardiovascular Disease. Original Policy Date

Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease

Total risk management of Cardiovascular diseases Nobuhiro Yamada

ARTICLE. Utility of Direct Measurement of Low-Density Lipoprotein Cholesterol in Dyslipidemic Pediatric Patients

SUPPLEMENTAL MATERIAL

In-Ho Chae. Seoul National University College of Medicine

Dyslipidemia Endothelial dysfunction Free radicals Immunologic

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Lipid Metabolism in Familial Hypercholesterolemia

Association of Major Modifiable Risk Factors Among Patients with Coronary Artery Disease - A Retrospective Analysis

KEY COMPONENTS. Metabolic Risk Cardiovascular Risk Vascular Inflammation Markers

CVD Prevention, Who to Consider

Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease

INTERNATIONAL JOURNAL OF INSTITUTIONAL PHARMACY AND LIFE SCIENCES

Yongyan Song 1, Yang Yang 2, Jingxiao Zhang 3, Yanmei Wang 3,4, Wenfeng He 3, Xiaoming Zhang 5, Jie Zhu 2 and Zhan Lu 3*

Statistical Fact Sheet Populations

EFFECT OF BIOCHEMICAL PARAMETERS SHOWING ATHEROGENICITY IN TYPE 2 DIABETIC NEPHROPATHY

Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution

Lipid Profile Analysis of Aircrew

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

1. Which one of the following patients does not need to be screened for hyperlipidemia:

Lipid profile in Diabetes Mellitus

ASSESSMENT OF INSULIN RESISTANCE AND Apo B / Apo A1 RATIO IN TYPE II DIABETES PATIENTS

Cardiovascular Complications of Diabetes

LDL How Low can (should) you Go and be Safe

Frequency of Dyslipidemia and IHD in IGT Patients

Acute coronary syndrome (ACS) is a major cause of morbidity and mortality

CLINICAL OUTCOME Vs SURROGATE MARKER

Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease


Impact of metabolic syndrome on hospital in acute myocardial infarction patients

Analysis of frequency of increased waist to hip ratio in patients of acute myocardial infarction

How would you manage Ms. Gold

Lipid Markers. Independent Risk Factors. Insulin Resistance Score by Lipid Fractionation

Supplementary Online Content

ISSN: X Impact factor: 4.295

POST GRADUATE DIPLOMA IN CLINICAL CARDIOLOGY (PGDCC) Term-End Examination June, 2015

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

Best Lipid Treatments

Apolipoprotein B in the Risk Assessment and Management of Cardiovascular Disease. Original Policy Date

Pathophysiology of Lipid Disorders

REVIEW ARTICLE REVIEW ARTICLE. Fasting versus non-fasting Lipid profile in the clinical practice

Changing lipid-lowering guidelines: whom to treat and how low to go

Transcription:

HK Tamang et al. (2013). Int J Appl Sci Biotechnol, Vol. 1(3): 106-109 DOI: 10.3126/ijasbt.v1i3.8583 ISSN 2091-2609

DOI: 10.3126/ijasbt.v1i3.8583 Research Article International Journal of Applied Sciences and Biotechnology ISSN: 2091-2609 SERUM LIPOPROTEIN (A) CONCENTRATION IS A BETTER PREDICTOR OF MYOCARDIAL INFARCTION THAN TRADITIONAL LIPID PROFILE AND LIPID RATIOS Abstract HK Tamang 1*, U Timilsina 2, KP Singh 3, R Shrestha 4, K Bist 4, L Maharjan 4 and S Shakya 4 1 Department of Biochemistry, Kantipur Dental College Teaching Hospital, Kathmandu, Nepal 2 Department of Medical Laboratory Technology, Kantipur Academy of Health Science, Kathmandu, Nepal 3 Department of Biochemistry, Institute of Medicine (TUTH), Kathmandu, Nepal 4 Department of Laboratory Medicine, Nobel College, Kathmandu, Nepal Corresponding author email: helosha@gmail.com Background- Lipoprotein (a) is a variant form of Low Density Lipoprotein (LDL) which comprises of an LDL like particle in which apo B-100 is firmly linked to apo-a glycoprotein. A large number of genetic and epidemiologic studies have identified Lipoprotein(a) as a risk factor for atherosclerotic diseases such as coronary heart disease and stroke. Based on our knowledge, this is the first study comparing Lipoprotein(a) with lipid profile and lipid ratios in Nepal. Aim & Objective- To compare the serum Lipoprotein(a) and Lipid panel concentrations in myocardial infarction patients and normal healthy control subjects. Materials & Methods- Study was carried out in 45 myocardial infarction patients as cases and 45 healthy subjects as controls. Lipoprotein(a) and Lipid profile tests were measured in serum using HumaStar 600 fully automated analyzer, Human, Germany. Results- Mean serum Lipoprotein(a) concentration in myocardial infarction group was significantly higher as compared to healthy controls. Lipid panel assays were not statistically significant among the groups. Conclusion- Our study revealed that myocardial infarction patients have elevated levels of serum Lipoprotein(a) as compared to healthy subjects. High concentration of serum Lipoprotein(a) is strongly associated with the risk of coronary heart disease. Keywords: - Lipoprotein(a), low density lipoprotein, myocardial infarction, lipid panel Introduction Lipoprotein(a) [Lp(a)], a genetically determined lipoprotein is composed of Low Density Lipoprotein (LDL) particle whose apolipoprotein B is bound to a plasminogen-like glycoprotein named apolipoprotein(a) (Utermann et al., 2001). Apolipoprotein(a), a member of plasminogenprothrombin family is found to interfere with the action of plasminogen and promotes thrombosis (Cobbaert et al., 1997). The prothrombotic nature of Lp(a) is supported by the studies that have shown the significant association of hyper-lp(a) and venous thrombosis (Sofi et al., 2007) and atherogenesis (Scanu et al., 1991). Coronary thrombosis formation is nowadays regarded as the most important cause of Acute Myocardial Infarction (AMI) (DeWood et al., 1980). Different studies have established Lp(a) as the independent risk factor for the development of atherosclerosis, genesis of AMI (Nguyen et al., 1997) and cerebrovascular diseases (Schwartzman et al., 1998). Serum Lp(a) is found to be higher in south Asians compared with Caucasians (Reddy et al., 1992) which is again confirmed by the finding that south Indian living in Britain had higher Lp(a) value than that of the white Europeans (Bhatnagar et al., 1995). These findings parallel with the increasing risk for myocardial infarction and cardiovascular death in migrants of south Asians than in other ethnic groups (Tuomilehto et al., 1984). Considering the role of Lp(a) in evolution of Acute Myocardial Infarction (AMI) and increasing burden of Cardiovascular Disease in south Asians we in our present study tried to investigate the predictive value of Lp(a) for AMI compared with traditional Lipid panel and ratios. Materials and Methods Study population- In this study a total number of 90 participants were included. 45 myocardial infarction (MI) positive participants (cases) admitted at Sahid Gangalal National Heart Center, Bansbari, Kathmandu, Nepal

and equal number of healthy participants (controls) aged above 30 years from Imadole and Gwarko communities of Lalitpur, Nepal were recruited. Patients with myocardial infarction were considered for our study after the confirmative diagnosis done by the cardiologist based on the findings of Electrocardiogram (ECG) and raised cardiac enzymes (Creatine Kinase MB, Lactate Dehydrogenase (LDH), Serum Glutarate Pyruvate Transminase(SGPT), Serum Glutarate Oxaloacetate Transaminase (SGOT) and Troponin I). All the participants except cases were asked for the history of diabetes, hormonal disorders, liver diseases, renal diseases and other chronic diseases. Those suspected of any disorders as indicated above were excluded. Sample Collection- After an overnight fast of at least 12 hours, blood samples were collected from the ante-cubital vein of each participant. Samples were collected in plain vials, allowed to clot, centrifuged at 3000rpm for 10 minutes and serum separated. Separated serum samples were preserved at -20 o C until assays were run. Biochemical Analysis- The lipid profile was done using CHOD-PAP method (Systemic Reagent for Humastar 600, Human, Germany). The Low Density Lipoprotein (LDL) was calculated using the Friedewald Formula (Friedewald et al., 1972). All the biochemical tests were run in the fully autoanalyzer (Humastar 600, Human, Germany). The serodos and serodos plus were used as the quality control samples and autocal as the standard to calibrate the tests. Both internal and external quality assurance tools were employed routinely to ensure the quality of test results. The Lp(a) concentration was measured using DRG ELISA Total Human Lipoprotein (a) (EIA- 4406), DRG International Inc., USA. The dynamic range of the Lp(a) ELISA assay kit was 3 µg/dl-405µg/dl. Ethical Clearance- Ethical clearance for the study was taken from Nepal Health Research Council, Nepal as per the Helsinki declaration of 1975. Statistical Analysis- All the statistical analysis were done using IBM SPSS Statistics (version 19) software. All tests of statistical significance were two sided with 95% confidence intervals (CI). Results A total of 90 subjects including equal numbers of MI cases and healthy normal controls were recruited in the study. The demographics of the study population are presented in Table-1. Plasma lipid profiles and Lipoprotein(a) of the groups are shown in Table-2. Lipid profile parameters were similar among the groups except for serum HDL Cholesterol which was significantly higher in normal controls (p= 0.026). Serum lipoprotein(a) value was significantly higher in MI cases (Figure-1) in comparison to the controls (p=0.004). Table 1- Demographics of study population MI Cases (n=45) Normal Controls (n=45) Sex Male Female N % N % 28 62.23 20 37.77 17 37.77 25 55.55 Age (inyears) 54.51±10.31 46.11±10.81 N= number of subjects, n= population size

Table 2- Lipid panel parameters and Lp(a) levels of study population Analyte MI Cases Normal Controls T Test P value Total Cholesterol (TC) (mmole/l) 4.314±1.155 4.267±0.658 0.827 Triglyceride (TG) (mmole/l) 1.793±0.948 1.708±0.920 0.683 HDL Cholesterol (mmole/l) 1.008±0.122 1.035±0.135 0.026* LDL Cholesterol (mmole/l) 2.452±1.131 2.418±0.407 0.864 TC /HDL Ratio 4.288±1.162 4.184±0.518 0.626 LDL/ HDL Ratio 2.485±1.002 2.459±0.451 0.891 Non HDL Cholesterol (mmole/l) 3.288±1.162 3.187±0.523 0.636 Lp(a) (µg/dl) 38.450±19.132 28.056±14.048 0.004** *Statistically significant **Statistically highly significant Fig. 1- Distribution of serum Lp(a) levels among the study groups Discussion Findings of this study showed no significant differences in Total Cholesterol (TC), Triglycerides (TG), LDL Cholesterol (LDL-C), TC/HDL ratio, LDL/HDL ratio and Non HDL-Cholesterol among the groups. Rather it showed the significant differences in Lp(a) level and HDL-C level among the group. Woo et al., (1993) observed higher mean TC, LDL-C and TG as well as lower mean HDL-C in AMI patients; high HDL-C was among the protective factors. Similarly Kumar et al., 2009 observed significantly higher TC and TG levels and lower HDL-C levels in AMI patients. Though in our study, the mean TC, TG, LDL- C, TC/HDL, LDL/HDL and non HDL-C were higher in AMI patients than that found in healthy participant, they were statistically not significant. In line with our findings, Lehto et al., 1993 did not find any difference in mean serum TC levels between the AMI patients and controls. The risk of AMI was associated with an increase in LDL-C and a decrease in HDL-C in both Asians and non-asians (Karthikeyan et al., 2009). Lower concentrations of serum HDL-C and higher

serum TG were found to be independent risk factors while serum LDL-C was not associated with AMI (Tokuda, 2005). Though different studies have shown lipid profile and lipid ratio to be promising in assessing the cardiovascular risk, there are some contradictory findings as mentioned above. Significantly higher value of Lp(a) and significantly lower value of HDL-C in AMI patients than in healthy participants indicate that Lp(a) is much better predictor of AMI than traditional lipid profile and lipid ratios. Conclusion Nowadays homocystein, hs-crp, Apo B/Apo A1 ratio, Lp(a) and other emerging risk factors are considered to be superior cardiovascular risk assessment tools. Our study also indicated that Lp(a) can be the better predictor of AMI. Moreover, for lipid profile patient preparation is required (Patients are required to be on at least 12 hours fast). In addition, Friedwald formula for calculating LDL-C is not valid if TG level is more than 4.2 mmol/l (450 mg/dl). Lp(a) on other hand is genetically determined and it doesn t fluctuate with diet. Taking all these in consideration we from the current study would like to project Lp(a) as the better predictor of AMI though there still remain some questions that limit its dissemination in clinical practice as mentioned by Pischon et al., 2005. The central question focuses on the cost-benefit relation associated with a change in the traditional clinical approach. References Bhatnagar D, Anand IS, Durrington PN, et al. (1995) Coronary risk factors in people from the Indian subcontinent living in West London and their siblings in India. Lancet 345:405 9. Cobbaert C, Jukema JW et al. (1997) Modulation of lipoprotein(a) atherogenicity by high density lipoprotein cholesterol levels in middle-aged men with symptomatic coronary artery disease and normal to moderately elevated serum cholesterol. J. Am. Coll. Cardiol. 30:1491-1499. DeWood MA, Spores J, Notsuke R et al. (1980) Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 303:897-902. Friedewald WT, Levy RI and Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 18:499 02. Karthikeyan G, Teo KK, Islam S, et al. (2009) Lipid profile, plasma apolipoproteins, and risk of a first myocardial infarction among Asians: an analysis from the INTERHEART Study. J Am Coll Cardiol.53:244 53. Kumar A, Nagtilak S, Sivakanesan R and Gunasekera S (2009) Cardiovascular risk factors in elderly normolipidemic acute myocardial infarct patients-a case controlled study from India. Southeast Asian J Trop Med Public Health.40:581 92. Lehto S, Palomaki P, Miettinen H, et al. (1993) Serum cholesterol and high density lipoprotein cholesterol distributions in patients with acute myocardial infarction and in the general population of Kuopio province, eastern Finland. J Intern Med. 233:179 85. Nguyen TT, Ellefson R, Hodge DO et al. (1997) Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9,936 men and women. Circulation 96:1390-1397. Pischon T, Girman CJ, Sacks FM, et al. (2005). Non-highdensity lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 112:3375 3383. Reddy S and Sanders TAB (1992) Lipoprotein risk factors in vegetarian women of Indian descent are unrelated to dietary intake. Atherosclerosis 95:223 9. Scanu AM, Lawn RM and Berg K (1991) Lipoprotein(a) and atherosclerosis. Ann Intern Med. 115:209-218. Schwartzman RA, Cox ID, Poloniecki J et al. (1998) Elevated plasma lipoprotein(a) is associated with coronary artery diseases in patients with chronic stable angina pectoris. J Am Coll Cardiol. 31:1260-1266. Sofi F, Marcucci R et al. (2007) Lipoprotein (a) and venous thromboembolism in adults: a meta-analysis. Am J Med. 120:728 33. Tokuda Y (2005) Risk factors for acute myocardial infarction among Okinawans. J Nutr Health Aging. 9:272 6. Tuomilehto J, Ram P, Eseroma R, et al. (1984) Cardiovascular diseases and diabetes mellitus in Fiji: analysis of mortality, morbidity and risk factors. Bull World Health Organ. 62:133 143. Utermann G (2001) Lipoprotein(a). In: Scriver CR, Beaudet AL, Sly WS, Valle D, (eds) The Metabolic and Molecular Bases of Inherited Disease. New York, McGraw-Hill Publishing Co, 2753 2787. Woo J, Ho SC, Wong SL, et al. (1993) Lipids, lipoproteins and other coronary risk factors in Chinese male survivors of myocardial infarction. Int J Cardiol. 39:195 202.